Artivion, Inc. (NYSE:AORT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $46.1667.

A number of brokerages have issued reports on AORT. Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Friday, April 10th. Needham & Company LLC decreased their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AORT. Royal Bank of Canada grew its position in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after purchasing an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Artivion by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after purchasing an additional 1,032 shares in the last quarter. Creative Planning grew its position in shares of Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after purchasing an additional 753 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Down 1.9%

Shares of AORT opened at $20.48 on Thursday. Artivion has a 52 week low of $19.16 and a 52 week high of $48.25. The firm has a market cap of $994.29 million, a P/E ratio of 85.35 and a beta of 1.26. The firm’s 50-day simple moving average is $29.52 and its 200 day simple moving average is $37.33. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.